Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 10/20 | 0.44 |
| ▸ | CA1 | P00915 | 9/20 | 0.44 |
| ▸ | CA2 | P00918 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.43 |
| ▸ | CA6 | P23280 | 4/20 | 0.43 |
| ▸ | CA5A | P35218 | 4/20 | 0.43 |
| ▸ | CA7 | P43166 | 4/20 | 0.43 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9393500 | 0.87 | TSHR (0.50) | TSHRLMNAKMT2AALDH1A1 | |
| SCHEMBL18343982 | 0.87 | TSHR (0.50) | TSHRLMNAKMT2AALDH1A1 | |
| SCHEMBL2454844 | 0.86 | TSHR (0.52) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL2454848 | 0.86 | TSHR (0.52) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL14278404 | 0.86 | TSHR (0.52) | TSHRCA12CA1CA2CA4 | |
| SCHEMBL21753464 | 0.85 | TSHR (0.51) | TSHRCA12CA9CA1CA2 | |
| SCHEMBL6303221 | 0.85 | TSHR (0.71) | TSHRCA12CA9CA1CA2 | |
| SCHEMBL6297105 | 0.85 | TSHR (0.48) | TSHRCA12CA9CA1CA2 | |
| SCHEMBL14740699 | 0.83 | TSHR (0.49) | TSHRCA12CA9CA1CA2 | |
| SCHEMBL4956715 | 0.82 | TSHR (0.46) | TSHRCA12CA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176363-A1 | Novel compounds and methods | PHARMAXIS PTY LTD. (AU) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176363-A1 | Novel compounds and methods | NFATC1, CD4, CCR5 | TSHR 4524/4885CA12 3956/4885CA9 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.